Drug Trial Radar · NCT04034823
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
59
Planned (sponsor's estimate)
Start
Sep 1, 2019
Primary completion
Jan 1, 2021
Study completion Jan 1, 2022
Sponsor
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single arm phase II trial to evaluate the efficacy, safety and tolerability of KN035 in combination with trastuzumab and docetaxel. Eligible patient will be enrolled and receive protocol defined therapies until progressive disease, unacceptable toxicity or withdrawal of informed consent. Tumor assessment will be performed according to RECIST 1.1 criteria.
Conditions
- HER2-positive Breast Cancer
Interventions
KN035Biological
KN035 5 mg/kg s.c. Q3W
TrastuzumabBiological
8 mg/kg IV loading followed by 6 mg/kg Q3W IV
DocetaxelDrug
100 mg/m2 Q3W IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective responseTime frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.